FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2287624209> ?p ?o ?g. }

• W2287624209 endingPage "S153" @default.
• W2287624209 startingPage "S153" @default.
• W2287624209 abstract "BackgroundIt is unclear whether tolvaptan can improve the mortality of heart failure.MethodsWe used tolvaptan for 107 patients with severe decompensated heart failure who already received substaitive conventional medical therapy including diuretics. However, 20 patients died during hospitalization after adding tolvaptan. We compared the clinical parameters including dose of furosemide and blood pressure before administering tolvaptan between patients who died during hospitalization (Death group) and patients who survived to discharge (Survival group) using univariate analysis. Multivariate analysis was performed using parameters which showed significant differences by univariate analysis.ResultsA Table.ConclusionsTable 1(PD1-7)Death group (n=20)Survival group (n=87)P value (univariate)ORP value (multivariate)Age74.9 ± 15.576.7 ± 9.50.895Male (n (%))14 (70)51 (58.6)0.449Use tolvaptan within 3 days after admission (n (%))5 (26)49 (56)0.0230.5240.350Serum-Na (mEq/l)130 ± 10.1136 ± 5.80.0041.0110.878Serum-K (mEq/l)4.1 ± 0.74.1 ± 0.60.743Serum-BUN (mg/dl)44.7 ± 28.240.5 ± 24.30.590Serum-Cr (mg/dl)1.83 ± 1.051.86 ± 1.180.978Hemoglobin (g/dl)10.0 ± 2.210.4 ± 2.20.541Serum-Albumin (g/dl)3.1 ± 0.83.3 ± 0.40.201Plasma osmolality (mOsm/L)283.1 ± 23.7294.5 ± 12.30.0160.9590.167Ejection Fraction (%)39.9 ± 17.846.8 ± 18.20.098Moderate and Severe Tricuspid regurgitation (n (%))10 (50)27 (31)0.124Inferior Vena Cava dilatation (n (%))10 (50)26 (29)0.115Systolic blood pressure (mmHg)97.4 ± 24.9119.7 ± 23.20.00020.9950.796Diastolic blood pressure (mmHg)52.4 ± 10.267.3 ± 17.30.00020.9180.006Tolvaptan (mg/dl)7.9 ± 3.48.3 ± 2.50.200Furosemide (mg/day)79.5 ± 74.239.7 ± 39.00.0221.0170.006Azosemide (mg/day)23.3 ± 34.625.5 ± 34.10.742Torasemide (mg/day)0.8 ± 2.500.00314.2850.119Spironolactone (mg/day)23.8 ± 22.213.8 ± 18.10.0421.0070.654Use of human atrial natriuretic peptide) (n (%))8 (40)31 (35.6)0.798 Open table in a new tab BackgroundIt is unclear whether tolvaptan can improve the mortality of heart failure. It is unclear whether tolvaptan can improve the mortality of heart failure. MethodsWe used tolvaptan for 107 patients with severe decompensated heart failure who already received substaitive conventional medical therapy including diuretics. However, 20 patients died during hospitalization after adding tolvaptan. We compared the clinical parameters including dose of furosemide and blood pressure before administering tolvaptan between patients who died during hospitalization (Death group) and patients who survived to discharge (Survival group) using univariate analysis. Multivariate analysis was performed using parameters which showed significant differences by univariate analysis. We used tolvaptan for 107 patients with severe decompensated heart failure who already received substaitive conventional medical therapy including diuretics. However, 20 patients died during hospitalization after adding tolvaptan. We compared the clinical parameters including dose of furosemide and blood pressure before administering tolvaptan between patients who died during hospitalization (Death group) and patients who survived to discharge (Survival group) using univariate analysis. Multivariate analysis was performed using parameters which showed significant differences by univariate analysis. ResultsA Table. A Table. ConclusionsTable 1(PD1-7)Death group (n=20)Survival group (n=87)P value (univariate)ORP value (multivariate)Age74.9 ± 15.576.7 ± 9.50.895Male (n (%))14 (70)51 (58.6)0.449Use tolvaptan within 3 days after admission (n (%))5 (26)49 (56)0.0230.5240.350Serum-Na (mEq/l)130 ± 10.1136 ± 5.80.0041.0110.878Serum-K (mEq/l)4.1 ± 0.74.1 ± 0.60.743Serum-BUN (mg/dl)44.7 ± 28.240.5 ± 24.30.590Serum-Cr (mg/dl)1.83 ± 1.051.86 ± 1.180.978Hemoglobin (g/dl)10.0 ± 2.210.4 ± 2.20.541Serum-Albumin (g/dl)3.1 ± 0.83.3 ± 0.40.201Plasma osmolality (mOsm/L)283.1 ± 23.7294.5 ± 12.30.0160.9590.167Ejection Fraction (%)39.9 ± 17.846.8 ± 18.20.098Moderate and Severe Tricuspid regurgitation (n (%))10 (50)27 (31)0.124Inferior Vena Cava dilatation (n (%))10 (50)26 (29)0.115Systolic blood pressure (mmHg)97.4 ± 24.9119.7 ± 23.20.00020.9950.796Diastolic blood pressure (mmHg)52.4 ± 10.267.3 ± 17.30.00020.9180.006Tolvaptan (mg/dl)7.9 ± 3.48.3 ± 2.50.200Furosemide (mg/day)79.5 ± 74.239.7 ± 39.00.0221.0170.006Azosemide (mg/day)23.3 ± 34.625.5 ± 34.10.742Torasemide (mg/day)0.8 ± 2.500.00314.2850.119Spironolactone (mg/day)23.8 ± 22.213.8 ± 18.10.0421.0070.654Use of human atrial natriuretic peptide) (n (%))8 (40)31 (35.6)0.798 Open table in a new tab" @default.
• W2287624209 created "2016-06-24" @default.
• W2287624209 creator A5001840266 @default.
• W2287624209 creator A5015963776 @default.
• W2287624209 creator A5023136502 @default.
• W2287624209 creator A5042840698 @default.
• W2287624209 creator A5052015187 @default.
• W2287624209 creator A5052477493 @default.
• W2287624209 creator A5086145494 @default.
• W2287624209 creator A5089046975 @default.
• W2287624209 date "2015-10-01" @default.
• W2287624209 modified "2023-10-14" @default.
• W2287624209 title "Adding Tolvaptan Instead of Increasing Dose of Furosemide for the Patients Already Received Low-Dose Furosemide May Improve Hospital Mortality" @default.
• W2287624209 doi "https://doi.org/10.1016/j.cardfail.2015.08.046" @default.
• W2287624209 hasPublicationYear "2015" @default.
• W2287624209 type Work @default.
• W2287624209 sameAs 2287624209 @default.
• W2287624209 citedByCount "0" @default.
• W2287624209 crossrefType "journal-article" @default.
• W2287624209 hasAuthorship W2287624209A5001840266 @default.
• W2287624209 hasAuthorship W2287624209A5015963776 @default.
• W2287624209 hasAuthorship W2287624209A5023136502 @default.
• W2287624209 hasAuthorship W2287624209A5042840698 @default.
• W2287624209 hasAuthorship W2287624209A5052015187 @default.
• W2287624209 hasAuthorship W2287624209A5052477493 @default.
• W2287624209 hasAuthorship W2287624209A5086145494 @default.
• W2287624209 hasAuthorship W2287624209A5089046975 @default.
• W2287624209 hasConcept C126322002 @default.
• W2287624209 hasConcept C126894567 @default.
• W2287624209 hasConcept C144301174 @default.
• W2287624209 hasConcept C164705383 @default.
• W2287624209 hasConcept C2777955127 @default.
• W2287624209 hasConcept C2778198053 @default.
• W2287624209 hasConcept C2779295919 @default.
• W2287624209 hasConcept C2780615674 @default.
• W2287624209 hasConcept C38180746 @default.
• W2287624209 hasConcept C71924100 @default.
• W2287624209 hasConcept C84393581 @default.
• W2287624209 hasConceptScore W2287624209C126322002 @default.
• W2287624209 hasConceptScore W2287624209C126894567 @default.
• W2287624209 hasConceptScore W2287624209C144301174 @default.
• W2287624209 hasConceptScore W2287624209C164705383 @default.
• W2287624209 hasConceptScore W2287624209C2777955127 @default.
• W2287624209 hasConceptScore W2287624209C2778198053 @default.
• W2287624209 hasConceptScore W2287624209C2779295919 @default.
• W2287624209 hasConceptScore W2287624209C2780615674 @default.
• W2287624209 hasConceptScore W2287624209C38180746 @default.
• W2287624209 hasConceptScore W2287624209C71924100 @default.
• W2287624209 hasConceptScore W2287624209C84393581 @default.
• W2287624209 hasIssue "10" @default.
• W2287624209 hasLocation W22876242091 @default.
• W2287624209 hasOpenAccess W2287624209 @default.
• W2287624209 hasPrimaryLocation W22876242091 @default.
• W2287624209 hasRelatedWork W1826340832 @default.
• W2287624209 hasRelatedWork W2064614679 @default.
• W2287624209 hasRelatedWork W2133725709 @default.
• W2287624209 hasRelatedWork W2144193318 @default.
• W2287624209 hasRelatedWork W2169170584 @default.
• W2287624209 hasRelatedWork W2190184375 @default.
• W2287624209 hasRelatedWork W2317696856 @default.
• W2287624209 hasRelatedWork W2734738746 @default.
• W2287624209 hasRelatedWork W2787247868 @default.
• W2287624209 hasRelatedWork W3034260459 @default.
• W2287624209 hasVolume "21" @default.
• W2287624209 isParatext "false" @default.
• W2287624209 isRetracted "false" @default.
• W2287624209 magId "2287624209" @default.
• W2287624209 workType "article" @default.